Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Alkermes plc (ALKS : NSDQ)
 
 • Company Description   
Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major therapeutic areas. Alkermes holds a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders including schizophrenia, depression, addiction and multiple sclerosis. Alkermes derives revenues on net sales of its proprietary products: Vivitrol & Aristada, and manufacturing and/or royalty revenues on net sales of products commercialized by the company's partners. These include Risperdal Consta, Invega Sustenna/Xeplion, Invega Trinza/Trevicta, Ampyra/Fampyra and Bydureon. Interesting late-stage candidate in the company's pipeline include nemvaleukin alfa developed for treating advanced solid tumors. Its proprietary drugs are Vivitrol & Aristada.

Number of Employees: 2,280

 
 • Price / Volume Information   
Yesterday's Closing Price: $29.28 Daily Weekly Monthly
20 Day Moving Average: 1,026,629 shares
Shares Outstanding: 166.12 (millions)
Market Capitalization: $4,864.04 (millions)
Beta: 0.60
52 Week High: $32.23
52 Week Low: $21.75
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.99% -1.88%
12 Week 8.85% 1.04%
Year To Date 12.06% 1.93%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1 BURLINGTON ROAD CONNAUGHT HOUSE
-
DUBLIN,L2 DUBLIN 4
IRL
ph: 353-1772-8000
fax: 781-890-0524
investor_relations@alkermes.com http://www.alkermes.com
 
 • General Corporate Information   
Officers
Richard F. Pops - Chairman and Chief Executive Officer
Iain M. Brown - Senior Vice President; Chief Financial Officer
Emily Peterson Alva - Director
Shane M. Cooke - Director
Richard B. Gaynor - Director

Peer Information
Alkermes plc (CORR.)
Alkermes plc (RSPI)
Alkermes plc (CGXP)
Alkermes plc (BGEN)
Alkermes plc (GTBP)
Alkermes plc (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G01767105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 07/26/23
Share - Related Items
Shares Outstanding: 166.12
Most Recent Split Date: 5.00 (2.00:1)
Beta: 0.60
Market Capitalization: $4,864.04 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.04 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.06 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/26/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.84
Price/Cash Flow: 116.02
Price / Sales: 4.34
EPS Growth
vs. Year Ago Period: -1,100.00%
vs. Previous Quarter: -400.00%
Sales Growth
vs. Year Ago Period: 3.25%
vs. Previous Quarter: -5.61%
ROE
03/31/23 - -5.02
12/31/22 - -3.32
09/30/22 - -1.10
ROA
03/31/23 - -2.69
12/31/22 - -1.80
09/30/22 - -0.60
Current Ratio
03/31/23 - 2.25
12/31/22 - 2.27
09/30/22 - 2.24
Quick Ratio
03/31/23 - 1.88
12/31/22 - 1.91
09/30/22 - 1.89
Operating Margin
03/31/23 - -4.67
12/31/22 - -3.17
09/30/22 - -1.05
Net Margin
03/31/23 - -14.65
12/31/22 - -14.23
09/30/22 - -11.41
Pre-Tax Margin
03/31/23 - -15.18
12/31/22 - -15.05
09/30/22 - -12.85
Book Value
03/31/23 - 6.05
12/31/22 - 6.35
09/30/22 - 6.35
Inventory Turnover
03/31/23 - 1.28
12/31/22 - 1.33
09/30/22 - 1.39
Debt-to-Equity
03/31/23 - 0.29
12/31/22 - 0.28
09/30/22 - 0.28
Debt-to-Capital
03/31/23 - 22.36
12/31/22 - 21.76
09/30/22 - 21.81
 

Powered by Zacks Investment Research ©